10 September 2020
Release date 9 September 2020
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces the appointment of Mr Fred Bart as Non-Executive Chair, allowing ExecutiveChair and CEO, Dr Graham Kelly, to focus on the CEO role.
Dr Kelly assumed both roles with the departure in mid-2019 of the previous CEO. While this was always regarded as a temporary measure, recent expansion of the Company’s R&D and commercial activities has brought to a head the need to split the roles. This will allow Dr Kelly to focus on running the Company’s business in conjunction with his senior executive team of Dr Gisela Mautner (CMO) and Jeanette Bell (COO).
Dr Kelly said, ‘The appointment of Mr Bart to the Noxopharm Board a few months ago brought an injection of business skills which the Board was keen to see exploited more fully by his appointment as Non-Executive Chair. At heart, Noxopharm is driven by a blend of science and entrepreneurship. But with exponential growth comes the need for hard-nosed business skills, which Fred brings. I look forward to working with Fred to deliver on what we both see as a major commercial opportunity’.
Mr Fred Bart said, ‘I am honoured to take on this role and look forward to working closely with the board and management in the exciting next chapter of the company’s development.’
Dr Kelly remains as CEO and on the Noxopharm Board as Managing Director.
